Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Cancer Cell
|
June 15, 2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells
Ann Mullally, Steven W Lane, Brian Ball, et al.
Leukemia
|
December 6, 2022
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response
Jonas S Jutzi, Anna E Marneth, María José Jiménez-Santos, et al.
Blood
|
March 15, 2013
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
Ann Mullally, Claudia Bruedigam, Luke Poveromo, et al.
Cancer Science
|
November 22, 2021
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
Hisashi Takei, Juan Luiz Coelho-Silva, Cristina Tavares Leal, et al.
Blood Advances
|
April 6, 2021
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis
Jeanne F Rivera, April J Baral, Fatima Nadat, et al.
Nature Materials
|
July 11, 2022
Mechanical checkpoint regulates monocyte differentiation in fibrotic niches
Kyle H Vining, Anna E Marneth, Kwasi Adu-Berchie, et al.
Blood
|
June 28, 2022
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs
Jonas S Jutzi, Anna E Marneth, Michele Ciboddo, et al.
Nature Medicine
|
November 17, 2015
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen, Qiong Yang, Benjamin Goldenson, et al.
Experimental Hematology
|
December 18, 2021
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms
Debra Van Egeren, Baransel Kamaz, Shichen Liu, et al.
The Journal of Experimental Medicine
|
March 12, 2014
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Marcus Järås, Peter G Miller, Lisa P Chu, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Cancer Cell
|
June 15, 2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells
Ann Mullally, Steven W Lane, Brian Ball, et al.
Leukemia
|
December 6, 2022
CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response
Jonas S Jutzi, Anna E Marneth, María José Jiménez-Santos, et al.
Blood
|
March 15, 2013
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
Ann Mullally, Claudia Bruedigam, Luke Poveromo, et al.
Cancer Science
|
November 22, 2021
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
Hisashi Takei, Juan Luiz Coelho-Silva, Cristina Tavares Leal, et al.
Blood Advances
|
April 6, 2021
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis
Jeanne F Rivera, April J Baral, Fatima Nadat, et al.
Nature Materials
|
July 11, 2022
Mechanical checkpoint regulates monocyte differentiation in fibrotic niches
Kyle H Vining, Anna E Marneth, Kwasi Adu-Berchie, et al.
Blood
|
June 28, 2022
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs
Jonas S Jutzi, Anna E Marneth, Michele Ciboddo, et al.
Nature Medicine
|
November 17, 2015
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen, Qiong Yang, Benjamin Goldenson, et al.
Experimental Hematology
|
December 18, 2021
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms
Debra Van Egeren, Baransel Kamaz, Shichen Liu, et al.
The Journal of Experimental Medicine
|
March 12, 2014
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Marcus Järås, Peter G Miller, Lisa P Chu, et al.
Page
of 7